Clinical Trials
121 trialsA Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China
Guangdong Association of Clinical Trials
Clinical Study on the Prevention of Driver Gene Negative Ib-IIIb Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors
Shanghai University of Traditional Chinese Medicine
WU-KONG36
Sichuan University
Multidisciplinary Treatment of Stage III ALK+ NSCLC With Neoadjuvant Alectinib and Chemotherapy
Guangdong Provincial People's Hospital
NEORADJUVANT
University of Maryland, Baltimore
Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLC
Peking University Cancer Hospital & Institute
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
INSTAR
Yonsei University
TD-ENSEMBLE
Tang-Du Hospital
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
PrECOG, LLC.
Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung Cancer
Hunan Province Tumor Hospital
GIVEN
Guangdong Provincial People's Hospital
Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients
Guangzhou University of Traditional Chinese Medicine
TOP 2301: Neoadjuvant Chemo for NSCLC
Duke University
An Exploratory Study of QL1706 Plus Chemotherapy in Perioperative NSCLC
Peking Union Medical College Hospital
NIRVANA-LUNG
UNICANCER
IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
University of Rochester
PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
University of Washington
QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC
Anhui Provincial Cancer Hospital
Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage â…¡A-â…¢B Non-small Cell Lung Cancer
Sichuan University
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Alliance for Clinical Trials in Oncology
PACCELIO
TheraOp
HYPERBOLIC
Università Vita-Salute San Raffaele
A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
PRIMM
University Medical Centre Maribor
Survival Analysis and Prognostic Biomarker Exploration of Postoperative Adjuvant Therapy Patterns in Patients With Non-small Cell Lung Cancer After Neoadjuvant Immunotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI
Fudan University
Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Resectable NSCLC (ECTOP-1013)
Fudan University
Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial
First Affiliated Hospital of Wenzhou Medical University
NEOpredict-EGF
University Hospital, Essen
Iparomlimab and Tuvonralimab Plus Chemotherapy for Inducing Conversion to Resectability in Initially Unresectable Stage III NSCLC
Shanghai Pulmonary Hospital, Shanghai, China
PRIME-Lung
Trans Tasman Radiation Oncology Group
Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC
The First Affiliated Hospital of Zhengzhou University
IRRADIATE-Lung
NYU Langone Health
Zusanli (ST36) Electroacupuncture Treatment for Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
West China Hospital
Clinical Outcomes of Tislelizumab Combined With Chemotherapy as Induction Therapy in Stage III (cTNM-IIIB/IIIC) NSCLC
West China Hospital
Efficacy and Safety of Chemoimmunotherapy and Carbon Ion Radiotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer
Zhejiang Cancer Hospital
A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status
China Medical University, China
CHORUS
Memorial Sloan Kettering Cancer Center
D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC
Guangdong Provincial People's Hospital
SACTION2401
Sun Yat-sen University
SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Fudan University
Induction Chemo-Nivo in Unresectable Stage III NSCLC
University of Kentucky
Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC
Tianjin Medical University Cancer Institute and Hospital
DIAL
Intergroupe Francophone de Cancerologie Thoracique
CLASSIC5
Hunan Province Tumor Hospital
Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer
Hunan Province Tumor Hospital
AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer
IRCCS San Raffaele
Chemotherapy Plus Immunotherapy Combined With SBRT as Neoadjuvant Therapy for Patients With Resectable NSCLC
First People's Hospital of Hangzhou